NBY
Novabay Pharmaceuticals Inc
AMEX · Pharmaceuticals
$0.76
+0.01 (+1.10%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.54M | 19.57M | 22.58M |
| Net Income | 6.11M | 4.44M | 4.92M |
| EPS | — | — | — |
| Profit Margin | 28.4% | 22.7% | 21.8% |
| Rev Growth | +9.2% | -0.9% | +13.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 16.37M | 20.34M | 18.54M |
| Total Equity | 40.94M | 41.21M | 43.15M |
| D/E Ratio | 0.40 | 0.49 | 0.43 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 8.25M | 7.02M | 9.17M |
| Free Cash Flow | 2.56M | 4.00M | 3.41M |